Which has better earnings and valuation, BHVN or PROK?

ProKidney has higher revenue and earnings than Biohaven. ProKidney is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A ProKidney $889K 535.15 -$68.99M -$0.53 N/A

Is BHVN or PROK more profitable?

Biohaven has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% ProKidney -8,131.50% N/A -21.39%

Does the media refer more to BHVN or PROK?

In the previous week, Biohaven had 3 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Biohaven and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.62 beat Biohaven's score of 0.40 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PHVS or PROK?

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A ProKidney $889K 535.15 -$68.99M -$0.53 N/A

Is PHVS or PROK more profitable?

Pharvaris has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% ProKidney -8,131.50% N/A -21.39%

Does the media prefer PHVS or PROK?

In the previous week, Pharvaris had 2 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Pharvaris and 2 mentions for ProKidney. Pharvaris' average media sentiment score of 1.15 beat ProKidney's score of 0.62 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or PROK?

In the previous week, Ocular Therapeutix had 4 more articles in the media than ProKidney. MarketBeat recorded 6 mentions for Ocular Therapeutix and 2 mentions for ProKidney. Ocular Therapeutix's average media sentiment score of 1.35 beat ProKidney's score of 0.62 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HRMY or PROK?

In the previous week, Harmony Biosciences had 5 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for Harmony Biosciences and 2 mentions for ProKidney. Harmony Biosciences' average media sentiment score of 1.26 beat ProKidney's score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ProKidney (PROK) Competitors

$1.58 -0.03 (-1.56%)

As of 01:48 PM Eastern

Compare

PROK vs. ABCL, BHVN, PHVS, OCUL, and HRMY

Should you buy ProKidney stock or one of its competitors? MarketBeat compares ProKidney with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProKidney include AbCellera Biologics (ABCL), Biohaven (BHVN), Pharvaris (PHVS), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

How does ProKidney compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AbCellera Biologics has a net margin of -181.75% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
ProKidney	-8,131.50%	N/A	-21.39%

In the previous week, ProKidney had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 2 mentions for ProKidney and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat ProKidney's score of 0.62 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
AbCellera Biologics	Very Positive
ProKidney	Positive

ProKidney has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$79.21M	23.76	-$146.41M	-$0.48	N/A
ProKidney	$889K	535.15	-$68.99M	-$0.53	N/A

AbCellera Biologics currently has a consensus price target of $8.00, indicating a potential upside of 29.81%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 661.90%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

AbCellera Biologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Summary

AbCellera Biologics and ProKidney tied by winning 8 of the 16 factors compared between the two stocks.

How does ProKidney compare to Biohaven?

Biohaven (NYSE:BHVN) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

In the previous week, Biohaven had 3 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Biohaven and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.62 beat Biohaven's score of 0.40 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
ProKidney	-8,131.50%	N/A	-21.39%

Biohaven presently has a consensus price target of $21.63, suggesting a potential upside of 51.01%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 661.90%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

ProKidney has higher revenue and earnings than Biohaven. ProKidney is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
ProKidney	$889K	535.15	-$68.99M	-$0.53	N/A

88.8% of Biohaven shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biohaven has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Summary

ProKidney beats Biohaven on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Pharvaris has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
ProKidney	-8,131.50%	N/A	-21.39%

In the previous week, Pharvaris had 2 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Pharvaris and 2 mentions for ProKidney. Pharvaris' average media sentiment score of 1.15 beat ProKidney's score of 0.62 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
ProKidney	$889K	535.15	-$68.99M	-$0.53	N/A

Pharvaris currently has a consensus price target of $50.08, indicating a potential upside of 48.84%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 661.90%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Pharvaris has a beta of -2.34, suggesting that its share price is 334% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

51.6% of ProKidney shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ProKidney beats Pharvaris on 10 of the 15 factors compared between the two stocks.

How does ProKidney compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Ocular Therapeutix has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Ocular Therapeutix presently has a consensus target price of $25.11, suggesting a potential upside of 178.21%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 661.90%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ocular Therapeutix had 4 more articles in the media than ProKidney. MarketBeat recorded 6 mentions for Ocular Therapeutix and 2 mentions for ProKidney. Ocular Therapeutix's average media sentiment score of 1.35 beat ProKidney's score of 0.62 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a net margin of -558.24% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
ProKidney	-8,131.50%	N/A	-21.39%

ProKidney has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	38.04	-$265.94M	-$1.46	N/A
ProKidney	$889K	535.15	-$68.99M	-$0.53	N/A

Summary

ProKidney beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Harmony Biosciences had 5 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for Harmony Biosciences and 2 mentions for ProKidney. Harmony Biosciences' average media sentiment score of 1.26 beat ProKidney's score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 16.20% compared to ProKidney's net margin of -8,131.50%. Harmony Biosciences' return on equity of 17.19% beat ProKidney's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
ProKidney	-8,131.50%	N/A	-21.39%

Harmony Biosciences has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$899.11M	2.14	$158.69M	$2.48	13.41
ProKidney	$889K	535.15	-$68.99M	-$0.53	N/A

Harmony Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Harmony Biosciences presently has a consensus target price of $42.50, suggesting a potential upside of 27.80%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 661.90%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Harmony Biosciences beats ProKidney on 11 of the 15 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$475.74M	$3.01B	$6.85B	$12.56B
Dividend Yield	N/A	2.08%	2.68%	9.45%
P/E Ratio	-2.97	20.00	27.17	24.29
Price / Sales	535.15	488.37	510.33	88.09
Price / Cash	N/A	56.68	48.63	60.03
Price / Book	-0.47	4.24	10.81	6.24
Net Income	-$68.99M	$65.46M	$3.59B	$331.73M
7 Day Performance	-12.50%	-3.70%	-2.34%	-1.70%
1 Month Performance	-6.80%	1.92%	3.01%	-0.76%
1 Year Performance	-57.77%	18.40%	25.50%	18.46%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.6645 of 5 stars	$1.58 -1.6%	$12.00 +661.9%	-52.5%	$475.74M	$889K	N/A	3
ABCL AbCellera Biologics	2.538 of 5 stars	$7.10 -7.7%	$8.33 +17.4%	+71.1%	$2.35B	$75.13M	N/A	500	Positive News
BHVN Biohaven	3.575 of 5 stars	$16.72 +7.5%	$21.63 +29.4%	+11.9%	$2.34B	N/A	N/A	239
PHVS Pharvaris	4.3689 of 5 stars	$35.92 +3.8%	$49.64 +38.2%	+52.9%	$2.26B	N/A	N/A	30	News Coverage Positive News Analyst Upgrade High Trading Volume
OCUL Ocular Therapeutix	3.4445 of 5 stars	$10.27 -0.6%	$25.11 +144.5%	-10.2%	$2.26B	$51.95M	N/A	230	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. ABCL, BHVN, PHVS, OCUL, and HRMY

How does ProKidney compare to AbCellera Biologics?

Summary

How does ProKidney compare to Biohaven?

Summary

How does ProKidney compare to Pharvaris?

Summary

How does ProKidney compare to Ocular Therapeutix?

Summary

How does ProKidney compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. ABCL, BHVN, PHVS, OCUL, and HRMY

How does ProKidney compare to AbCellera Biologics?

Do insiders and institutionals believe in ABCL or PROK?

Is ABCL or PROK more profitable?

Does the media refer more to ABCL or PROK?

Which has preferable valuation and earnings, ABCL or PROK?

Do analysts rate ABCL or PROK?

Which has more volatility & risk, ABCL or PROK?

Summary

How does ProKidney compare to Biohaven?

Does the media refer more to BHVN or PROK?

Is BHVN or PROK more profitable?

Do analysts prefer BHVN or PROK?

Which has better earnings and valuation, BHVN or PROK?

Do insiders and institutionals hold more shares of BHVN or PROK?

Which has more risk & volatility, BHVN or PROK?

Summary

How does ProKidney compare to Pharvaris?

Is PHVS or PROK more profitable?

Does the media prefer PHVS or PROK?

Which has stronger valuation and earnings, PHVS or PROK?

Do analysts rate PHVS or PROK?

Which has more volatility & risk, PHVS or PROK?

Do insiders & institutionals hold more shares of PHVS or PROK?

Summary

How does ProKidney compare to Ocular Therapeutix?

Which has more volatility & risk, OCUL or PROK?

Do analysts recommend OCUL or PROK?

Do insiders and institutionals believe in OCUL or PROK?

Does the media favor OCUL or PROK?

Is OCUL or PROK more profitable?

Which has preferable earnings & valuation, OCUL or PROK?

Summary

How does ProKidney compare to Harmony Biosciences?

Do insiders and institutionals hold more shares of HRMY or PROK?

Does the media prefer HRMY or PROK?

Is HRMY or PROK more profitable?

Which has stronger earnings and valuation, HRMY or PROK?

Which has more risk & volatility, HRMY or PROK?

Do analysts recommend HRMY or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools